menu
    • menu
    [{"orgOrder":0,"company":"Aerogen","sponsor":"Polarean","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerogen \/ Aerogen","highestDevelopmentStatusID":"6","companyTruncated":"Aerogen \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Aerogen","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Aerogen \/ Aerogen","highestDevelopmentStatusID":"9","companyTruncated":"Aerogen \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Aerogen","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerogen \/ Aerogen","highestDevelopmentStatusID":"1","companyTruncated":"Aerogen \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerogen \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Epoprostenol Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aerogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Undisclosed"},{"orgOrder":0,"company":"Aerogen","sponsor":"Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Epoprostenol Sodium","moa":"Prostanoid IP receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerogen \/ Ohio State University","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Ohio State University"},{"orgOrder":0,"company":"Aerogen","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"AP-002","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists||RANKL","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20999999999999999,"dosageForm":"Inhalation","sponsorNew":"Aerogen \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Aerogen"},{"orgOrder":0,"company":"Aerogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AP-002","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerogen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aerogen \/ Undisclosed"},{"orgOrder":0,"company":"Aerogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AP-002","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Undisclosed"},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aerogen \/ CanSino Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aerogen \/ CanSino Biologics"},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aerogen \/ CanSino Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aerogen \/ CanSino Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Aerogen

    Menu

    Aerogen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : Università degli Studi di Ferrara

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC

                            Details : Salbutamol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Insufficiency.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 07, 2025

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Università degli Studi di Ferrara

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SF-RI 1

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

                            Details : AeroFact (SF-RI 1) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Distress Syndrome.

                            Product Name : AeroFact

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 15, 2025

                            Lead Product(s) : SF-RI 1

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : Polarean

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Usin...

                            Details : Albuterol Sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2024

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : Polarean

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ad5-nCoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : CanSino Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen and CanSinoBIO, First Public Bo...

                            Details : Convidecia Air™ (homologous inactivated covid-19 vaccine) has proven to be an innovative solution that provides safe and effective protection for people through a needle-free, painless and non-invasive delivery without any serious adverse events observ...

                            Product Name : Convidecia

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Ad5-nCoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : CanSino Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Recipient : Nuance Pharma

                            Deal Size : $212.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distres...

                            Details : The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in ...

                            Product Name : AeroFact

                            Product Type : Miscellaneous

                            Upfront Cash : $20.0 million

                            December 22, 2021

                            Lead Product(s) : AP-002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Recipient : Nuance Pharma

                            Deal Size : $212.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ad5-nCoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : CanSino Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Aerogen and CanSinoBIO Agree on Landmark Development and Commercial Supply Partnership for World’s First Inh...

                            Details : Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine, Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.

                            Product Name : Convidecia

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 09, 2021

                            Lead Product(s) : Ad5-nCoV

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : CanSino Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNG001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Recipient : Synairgen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies

                            Details : Synairgen’s SNG001 among the many potential treatments and vaccines to be delivered via Aerogen’s aerosol drug delivery system .

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 23, 2020

                            Lead Product(s) : SNG001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Recipient : Synairgen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epoprostenol Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Ohio State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

                            Details : Epoprostenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 30, 2020

                            Lead Product(s) : Epoprostenol Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Ohio State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SF-RI 1

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

                            Details : SF-RI 1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome, Newborn.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 31, 2019

                            Lead Product(s) : SF-RI 1

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epoprostenol Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery ...

                            Details : VentaProst (Epoprostenol) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension, Pulmonary.

                            Product Name : VentaProst

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 21, 2017

                            Lead Product(s) : Epoprostenol Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth